D-Lac3.35 gm/5 ml

D-Lac 3.35 gm/5 ml is an osmotic (hyperosmolar) laxative prescribed for the management of the following conditions:

Chronic Constipation

D-Lac 3.35 gm/5 ml is indicated for the treatment of chronic constipation and for maintaining regular, comfortable bowel movements. In every case of chronic constipation, first-line management should include a fiber-rich diet (vegetables, salads, and fruits), a generous intake of fluids, and adequate physical exercise. D-Lac 3.35 gm/5 ml is recommended only when these lifestyle measures alone prove insufficient to relieve symptoms.

Intestinal Flora Disturbances

D-Lac 3.35 gm/5 ml supports the restoration of healthy gut flora and is used in conditions where the intestinal microbiome is disrupted, including:

• Damage to intestinal flora, such as that following long-term antibiotic therapy
• Gall bladder disorders
• Intestinal diseases including colitis, diverticulosis, and megacolon

Elevated Blood Ammonia (Hepatic Conditions)

D-Lac 3.35 gm/5 ml is indicated for the reduction of raised blood ammonia levels (hyperammonaemia) associated with liver disease, including hepatopathy and portal-systemic (hepatic) encephalopathy. By lowering ammonia absorption from the gut, it helps improve the mental state of patients with hepatic encephalopathy.

D-Lac 3.35 gm/5 ml is a hyperosmolar laxative widely used as an effective and well-tolerated treatment for constipation. It is a synthetic, non-absorbable disaccharide that works by drawing water into the bowel through osmosis. This increased fluid content causes distention of the intestine, softens the stool, and accelerates bowel movement. Because it is not absorbed into the bloodstream in significant amounts, D-Lac 3.35 gm/5 ml acts locally within the colon, making it suitable for long-term use in adults, children, infants, and elderly patients when prescribed appropriately.

Osmotic purgatives (osmotic laxatives).

D-Lac 3.35 gm/5 ml is a synthetic disaccharide composed of galactose and fructose. It passes through the small intestine unchanged, as the body lacks the enzymes required to break it down. Upon reaching the colon, D-Lac 3.35 gm/5 ml is metabolized by saccharolytic (sugar-fermenting) bacteria into low-molecular-weight organic acids, primarily lactic acid, along with small amounts of acetic and formic acid.

These organic acids lower the pH of the colonic contents and promote the retention of water through an osmotic effect. The resulting increase in stool water content and volume stimulates peristaltic activity, easing the passage of stool. In hepatic encephalopathy, the acidification of the colon converts absorbable ammonia (NH₃) into non-absorbable ammonium ions (NH₄⁺), which are then excreted, thereby reducing blood ammonia concentration. Since D-Lac 3.35 gm/5 ml is only minimally absorbed, its systemic pharmacokinetics are not relevant to its principal therapeutic action.

D-Lac 3.35 gm/5 ml has no clinically significant drug interactions when used as directed. However, a few considerations should be noted:

• Excessive or prolonged misuse of D-Lac 3.35 gm/5 ml may cause potassium loss, which can intensify the effects of cardiac glycosides (such as digoxin).
• Concurrent use with other laxatives is generally not recommended during the treatment of hepatic encephalopathy, as loose stools may falsely suggest that an adequate D-Lac 3.35 gm/5 ml dose has been reached.
• Because D-Lac 3.35 gm/5 ml acidifies the colon, medications designed to release in a pH-dependent manner in the colon may theoretically be affected.

D-Lac 3.35 gm/5 ml is generally well tolerated. Mild side effects may occur, particularly at the start of treatment, and usually resolve as therapy continues or when the dose is adjusted. Commonly reported effects include:

• Flatulence (gas), which often subsides after the first few days of treatment
• Abdominal cramps and discomfort at the beginning of therapy, typically relieved by reducing the dose
• Nausea and vomiting
• Diarrhoea, usually associated with higher-than-recommended doses

Prolonged use or misuse at excessive doses may lead to loss of electrolytes, primarily potassium. If severe or persistent diarrhoea, dehydration, or electrolyte imbalance occurs, the dose should be reduced or treatment reviewed by a physician.

The US FDA Pregnancy Category of D-Lac 3.35 gm/5 ml is B. Available studies indicate that D-Lac 3.35 gm/5 ml has no known adverse effects on pregnancy, as it is minimally absorbed and acts locally within the gut. It is generally considered one of the safer laxative options during pregnancy and breastfeeding. Nevertheless, decisions regarding its use during pregnancy and lactation should be made by a registered physician after weighing the benefits and risks.

Certain precautions should be observed when using D-Lac 3.35 gm/5 ml:

• Administer with care to patients who are intolerant to D-Lac 3.35 gm/5 ml or have difficulty digesting sugars.
• The higher doses used in the treatment of hepatic (pre)coma contain a considerable amount of sugar, which should be taken into account in patients with diabetes mellitus.
• Prolonged use at high doses may cause diarrhoea and electrolyte disturbances; monitoring may be required, especially in the elderly and debilitated patients.
• If no therapeutic effect is observed after several days, or if constipation persists, consult a physician for reassessment.
• Patients with rare hereditary conditions such as galactose or fructose intolerance should avoid D-Lac 3.35 gm/5 ml.

There have been no reports of serious accidental overdose with D-Lac 3.35 gm/5 ml. In the event of acute overdose, the main symptoms are expected to be diarrhoea and abdominal cramps. Excessive dosing may also lead to fluid loss, dehydration, and electrolyte imbalance—particularly loss of potassium. Management is generally supportive: discontinue or reduce the dose, and correct any fluid or electrolyte disturbances. Seek medical attention if symptoms are severe or persistent.

Keep D-Lac 3.35 gm/5 ml in a dry place, protected from light and heat. Do not freeze. Keep the bottle tightly closed after use. Keep out of the reach of children. Do not use after the expiry date printed on the container.

Pediatric Use: D-Lac 3.35 gm/5 ml may be used in infants, toddlers, and children under close medical supervision, with the dose carefully adjusted for age and body weight. Special care is needed in infants to avoid dehydration and electrolyte imbalance.

Geriatric Use: Elderly patients can use D-Lac 3.35 gm/5 ml safely, but they may be more sensitive to fluid and electrolyte loss during prolonged therapy; monitoring is advisable.

Patients with Diabetes: The sugar content of D-Lac 3.35 gm/5 ml is usually negligible at normal laxative doses. However, the high doses used for hepatic encephalopathy require caution and possible dose adjustment in diabetic patients.

Hepatic and Renal Impairment: D-Lac 3.35 gm/5 ml is frequently used in liver disease and is not significantly absorbed, so dose adjustment for renal impairment is generally not required. Use should always be guided by a physician.